Summary
Stryker Corporation's 2010 Form 10-K highlights a year of solid growth, with total net sales increasing by 9% to $7.32 billion. This growth was driven by a combination of increased unit volume, strategic acquisitions, and favorable foreign currency exchange rates, partially offset by pricing changes. The company's performance was supported by strong sales in both its Orthopaedic Implants and MedSurg Equipment segments. The Orthopaedic Implants segment saw a 5% increase in sales, primarily driven by hip, knee, and trauma implant systems, while the MedSurg Equipment segment experienced a significant 16% jump, bolstered by surgical equipment, navigation systems, and patient handling products. The company also made strategic acquisitions throughout the year, including key assets in the neurovascular market, which are expected to enhance its product portfolio and market presence. Financially, Stryker demonstrated robust operational cash flow and a strong balance sheet, enabling it to fund acquisitions, dividends, and stock repurchases. Despite some ongoing legal and regulatory matters, the company maintained effective internal controls and expressed confidence in its ability to fund future operations and growth initiatives.
Financial Highlights
54 data points| Revenue | $7.32B |
| Cost of Revenue | $2.29B |
| Gross Profit | $5.03B |
| R&D Expenses | $394.00M |
| SG&A Expenses | $2.71B |
| Operating Expenses | $3.28B |
| Operating Income | $1.75B |
| Interest Expense | $53.00M |
| Net Income | $1.27B |
| EPS (Basic) | $3.21 |
| EPS (Diluted) | $3.19 |
| Shares Outstanding (Basic) | 396.40M |
| Shares Outstanding (Diluted) | 399.50M |
Key Highlights
- 1Stryker reported a 9% increase in net sales for 2010, reaching $7.32 billion, driven by strong performance in both major business segments.
- 2The MedSurg Equipment segment showed particularly robust growth, with sales up 16%, driven by surgical equipment and patient handling products.
- 3The company completed several strategic acquisitions during 2010, including significant assets in the neurovascular market, bolstering its product offerings.
- 4Net earnings increased by 15% year-over-year, reaching $1.27 billion, with diluted EPS growing to $3.19.
- 5Operational cash flow remained strong, providing ample resources for investments in R&D, acquisitions, and shareholder returns (dividends and share repurchases).
- 6Research and development expenses increased to 5.4% of sales, indicating a continued focus on innovation and new product development.